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Hereditary haemorrhagic telangiectasia (HHT) is a group of autosomal dominant disorders of
vascular structure. The IrishNational Centre forHHTat theMercyUniversityHospital, Cork, Ireland
was founded in 2003. From2003 to 2008, screening of 164 patientswith contrast echocardiography,
thoracic computerised tomography (CT) and cerebral magnetic resonance imaging (MRI) has iden-
tified 88 patients with definite HHT, 72 (82%) of whom had epistaxis, 70 (80%) had telangiectasia
and 81 (92%) had a first-degree relative with HHT. We sought to describe the manifestations of
HHT in an Irish population and to determine differences between internationally reported data.
The HHT patient database was analysed to describe demographics, clinical manifestations and
interventional procedures performed in all referred patients.
Contrast echocardiography and/or CTwere performed in 86 patients with definite HHT, identi-
fying 27 patients (31%) with pulmonary arteriovenous malformations (pAVMs). Nineteen patients
with single or multiple pAVMs had 28 embolisation procedures performed, with 1e6 pAVMs embo-
lised per procedure. Cerebral MRI was performed in 78 (89%) patients and 2 (2.3%) had cerebral
arteriovenous malformations (cAVMs).
HHT prevalence is thought to be 1 in 2500e8000, suggesting that there are many undiagnosed
cases in Irish patients. Internationally published data suggest a prevalence of 15e35% for pAVMs
and 10e23% for cAVMs in patients with HHT. While the prevalence of pAVMs in our group is consis-
tent with these data, the prevalence of cAVMs is considerably lower, suggesting that Irish patients
with HHT may differ genotypically and phenotypically from those in other countries.
ª 2010 Elsevier Ltd. All rights reserved.21 4935325; fax: þ353 21 4935350.
om.net (T.M. O’ Connor).
0 Elsevier Ltd. All rights reserved.
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Hereditary haemorrhagic telangiectasia (HHT) is a group of
autosomal dominant multisystem vascular dysplasias char-
acterised by recurrent epistaxis with cutaneous and mucosal
telangiectases (Fig. 1) and visceral arteriovenous malforma-
tions (AVMs).1 It is historically known as Rendu-Osler-Weber
syndrome, after three physicians who, in the late 19th and
early 20th century, recognised this hereditary disorder
involving nosebleeds and characteristic cutaneous and
mucosal red spots. The title HHT was devised by Hanes in
1909.1
HHT affects 1 in 8000e10,000 individuals but is subject
to ethnic and geographical variation, with prevalence
reported as 1 in 2500 in some regions of France.2 Pene-
trance and expressivity are also subject to variation, even
within a single affected family,2 that is, an affected indi-
vidual with epistaxis, telangiectasia and pulmonary AVMs
may have a sibling with epistaxis only. A number of HHT
subtypes have been identified including HHT type 1, asso-
ciated with an endoglin gene mutation (chromosome 9) and
HHT type 2 associated with an ALK-1 (AC-VRL1) gene
mutation (chromosome 12). Other chromosomes involved in
HHT include chromosomes 5, 7 and 18 (MADH4 or SMAD4
gene).2,3 These genes encode proteins expressed on
vascular endothelial cells which are involved with signalling
by the transforming growth factor-beta (TGF-b) family.
TGF-b signalling affects cellular growth and differentiation.
Thus abnormal angiogenesis in HHT is thought to occur due
to aberrant TGF-b signalling caused by disturbed protein
function from endoglin and ALK-1 genetic mutations.4
Genetic testing may help to diagnose HHT in a patient
with an affected relative who has a known HHT mutation.5
The understanding of HHT and its complications
continues to evolve since this condition was first recog-
nised. The Scientific Advisory Board of the HHT Foundation
International established clinical criteria for the diagnosis
of HHT (the Curac¸ao criteria) in 1998 (Table 1). HHT diag-
nosis is considered definite if three criteria are present,Figure 1 67 Year male with HHT and mpossible or suspected if two criteria are present and
unlikely if fewer than two criteria are present.6 More
recently, international guidelines for the diagnosis and
management of HHT have been published.7
HHT is a relatively common but under-recognised condi-
tion. The importance of screening for this disorder must be
emphasised as up to 10% of affected individuals suffer
disability or premature death as a result of complications
associated with HHT.5 These complications are often due to
an AVM’s increased likelihood of rupture when compared
with a regular blood vessel. In the case of pulmonary AVMs
(pAVMs) (Fig. 2) complications also arise from right-to-left
shunting of blood leading to cerebrovascular accident or
brain abscess due to bland or septic emboli entering the
cerebral circulation.8 Therefore, all patients with suspected
or confirmed HHT, as well as first-degree relatives of definite
cases, should be referred to a specialist centre for appro-
priate screening.2
The Irish National HHT Centrewas established in theMercy
University Hospital (MUH) in Cork, Ireland in January 2003.
This centre aims to identify patients with this condition, to
identify all affected family members through screening, to
identify the manifestations of HHT in each person affected
and to manage these appropriately. Screening tests for
visceral AVMs include contrast echocardiography, compu-
terised tomography (CT) of thorax and magnetic resonance
imaging (MRI) of brain. Interventions for epistaxis, pAVMs and
cerebral AVMs (cAVMs) are carried out as necessary and
include nasal cautery, nasal septal dermoplasty, nasal graft-
ing and AVM embolisation. This paper reports the experience
of the Irish National HHT centre from 2003 to 2008, with
particular reference to the prevalence of AVMs in this patient
population compared with other international data.
Methods
Patients referred to the Irish National HHT Centre were
invited to attend for clinical history andphysical examination;
further investigations in those with clinical features of HHTultiple mucocutaneous telangiectasia.
Evidence of HHT
Contrast Echocardiography Cerebral MRI if > 7yrs
Negative Positive for pAVMs
Thoracic CTNegative
PositiveFeeding artery 
<3mm
Embolize
Repeat CT at 6 months 
to confirm occlusion
Follow-up at 5 yr 
interval (3 yr interval 
age 12-18, frequently 
in pregnancy)
Antibiotic prophylaxis 
for dental/surgical 
procedures when 
pAVMs not excluded 
by negative echo-
bubble 
Follow-up
Rescreen if 
cerebral white 
matter lesions 
on MRI 
Feeding artery 
≥3mm
Figure 3 Screening and management algorithm for patients
with suspected HHT.
Table 1 Curac¸ao criteria for the diagnosis of HHT.
Spontaneous and recurrent epistaxis
Multiple telangiectasia at characteristic sites
including face, lips, oral mucosa and fingers
Visceral involvement: gastrointestinal telangiectasia
(with or without bleeding) or visceral AVMs
(pulmonary, cerebral, hepatic or spinal)
Family history: first-degree relative affected
(in accordance with these criteria)
HHT diagnosis is considered definite if three criteria are
present, possible or suspected if two criteria are present and
unlikely if fewer than two criteria are present.6
1220 C.F. Ni Bhuachalla et al.included contrast echocardiography and contrast-enhanced
cerebral MRI, according to an established management algo-
rithm (Fig. 3). Among the patients referred, 69% were
screened because of a family history of HHT and the
remainder had epistaxis, telangiectasia and/or pAVMs
detected by other physicians and were therefore screened.
Contrast echocardiography, also known as an ‘echo-
bubble’ study, involves injecting 10 ml of agitated saline
into a peripheral vein and observing its course through the
cardiac chambers with transthoracic echocardiography.
Under normal circumstances, minute air bubbles appear
rapidly in the right heart and then dissipate as they are
filtered in the pulmonary circulation. An intracardiac shunt
manifests as bubbles appearing in the left heart chambers
within one cardiac cycle of appearing in the right side of
the heart. When the patient has a pAVM, bubbles will be
visualised in the left heart chambers after three to 8
cardiac cycles as the bubbles are shunted through the
AVM.9
Patients with a positive echo-bubble in this study pro-
ceeded to non-contrast CT thorax (Siemens Somatom
volume zoom CT) to identify pAVMs. Pulmonary AVMs with
feeding arteries of more than 3 mm diameter were
embolised. Feeding arteries were localised by selective
pulmonary angiography. The feeding arteries were then
selectively cannulated and embolised using stainless steelFigure 2 Typical pAVM in a patient with definite HHT with
a large feeding vessel.coils (Cook, Denmark) or Amplatzer plugs (AGA Medical,
Plymouth, Maine, USA). Follow-up is by non-contrast CT
thorax, usually six months after a successful embolisation,
and 3e5 yearly thereafter.2 Rapid pAVM enlargement can
occur during puberty and pregnancy. Increased frequency
of screening is recommended during these intervals.10 A
typical pAVM with a large feeding vessel is shown in Fig. 2.
Figs. 4 and 5 show a pAVM and embolisation of a pAVM (both
using pulmonary angiography).
The MRI studies of patients in whom cAVMs were iden-
tified were reviewed by a consultant neuroradiologist with
extensive neuro-vascular embolisation experience; his
assessment of the need for further intervention for cAVMs
was followed. Patients with mucocutaneous manifesta-
tions, epistaxis or GI telangiectasia were assessed as
needed by a Consultant Dermatologist, ENT surgeon or
Gastroenterologist. In general, screening for liver disease in
HHT is not routinely recommended, as most affected
patients are asymptomatic.2
Data were recorded prospectively from patients with
suspected HHT. Details recorded included demographics of
the index case and of family members affected, clinical
features of the index case, screening tests carried out and
their results, treatment of pAVM, cAVM and epistaxis, and
follow up information. The database, at the time of
analysis, consisted of one hundred and sixty-four patients
from 43 families from all over Ireland. Patients were male
and female, ranging in age from 7 to 71 years. Statistical
analysis was carried out using SPSS software (SPSS, Chi-
cago, IL).
Figure 4 pAVM with feeding artery and draining vein (pulmo-
nary angiography).
Figure 5 Complete embolisation of feeding artery with stain-
less steel coils (pulmonary angiography).
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Between 2003 and 2008, screening of one hundred and sixty-
four patients and their families identified 88 patients (54%)
with definiteHHT (based on thepresence of 3 ormoreCurac¸ao
criteria), 26 patients (16%) with possible or suspected HHT
(based on the presence of 2 Curac¸ao criteria) and 50 patients
(30%) unlikely to have HHT (based on the presence of fewer
than 2 Curac¸ao criteria) (Table 2). Results of cAVM and pAVM
screening were incorporated into the clinical diagnosis for
each patient. Among the screened population, forty-two
percent were male, 84% had a family history of HHT, 56% had
a history of epistaxis and 57% had cutaneous telangiectasia.
Among the group of eighty-eight patients with definite
HHT, 53%weremale, 92% had a family history of HHT, 82% had
a history of epistaxis and 80% had cutaneous telangiectasia
(Table 3). Contrast echocardiography and/or non-contrast CT
were performed in eighty-six patients, identifying 27 patients
(31%) with pAVMs. Nineteen patients with single or multiple
pAVMs had 28 embolisation procedures performed, with 1e6
pAVMs embolised per procedure. While pleuritic chest pain
was common (20%) after pAVM embolisation, the only serious
complication was migration of a 12 mm Cook Nester coil to
the left lower limbduring attemptedembolisation in a patient
with a large pAVM with a 13 mm feeding artery. The device
was successfully retrieved with a snare and the pAVM was
embolised without further complications.
Contrast-enhanced cerebral MRI was performed in
seventy-eight patients (89%), 1 of whom had a small cAVM
requiring follow up only. One patient had a previously
diagnosed cAVM which had bled many years previously,
resulting in a significant neurological deficit. It was felt that
no new intervention was required for this cAVM. No patient
had other vascular malformations of cerebral vessels.
Thirty-two families (out of 43 assessed) with at least one
member with definite HHT were identified.
Among the group of twenty-six patients with possible or
suspected HHT, 31% were male, 85% had a family history of
HHT, 69% had a history of epistaxis and 65% had cutaneous
telangiectasia (Table 3). Contrast echocardiography and/or
non-contrast CT were performed in twenty-six patients,
identifying 5 patients (19%) with pulmonary pAVMs, none of
which fulfilled the criteria for embolisation. Contrast-
enhanced cerebral MRI was performed in twenty-five
patients (96%), none of whom had cAVMs.
Among the group of fifty patients unlikely to haveHHT, 28%
weremale, 68%had a family history ofHHT, 4%had ahistory of
epistaxis and 12% had cutaneous telangiectasia (Table 3).
Contrast echocardiography and/or non-contrast CT were
performed in forty-four patients, but no pAVMs were detec-
ted. Contrast enhanced cerebral MRI was performed in thirty-
eight patients (76%), none of whom had cAVMs.
No cases of pulmonary hypertension were detected,
either by echocardiography during screening or by direct
measurement of pulmonary artery pressure in those who
had pAVM embolisation.
Discussion
One hundred and sixty-four subjects were screened in the
Irish National HHT centre from 2003 to 2008. More than half
Table 2 Baseline characteristics of the screened
population.
Characteristics Number %
Total screened 164
Gender
Male 69 42.1
Female 95 57.9
Age at screening (yrs)
0e25 58 35.4
26e50 79 48.1
51e75 27 16.5
Family history of HHT 137 83.5
Epistaxis 92 56.1
Telangiectasia 93 56.7
HHT Diagnosis
Definite 88 54
Possible/Suspected 26 16
Unlikely 50 30
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and one third of this group had pAVMs of which 70% required
embolisation. Two patients (2.3%) with definite HHT had
cAVMs, one that had already bled and 1 that was considered
too small to require embolisation. Other complications suchTable 3 HHT-specific diagnosis and management.
Definite
HHT
Suspected
HHT
Unlikely
HHT
Number 88 26 50
Age at screening (yrs) 41.4 
14.69
37.3 
17.59
29.8 
15.06
<18 yrs at screening 3 (3.4%) 4 (15.4%) 10 (20%)
Gender
Male 47 (53%) 8 (31%) 14 (28%)
Female 41 (47%) 18 (69%) 36 (72%)
Family History
of HHT
81 (92%) 22 (85%) 34 (68%)
Epistaxis 72 (82%) 18 (69%) 2 (4%)
Epistaxis treatment
Nasal cautery 16 (18%) 5 (19%) 0
Septodermoplasty 2 (2%) 0 0
Skin Graft 1 (1%) 0 0
Telangiectasia 70 (80%) 17 (65%) 6 (12%)
Contrast Echo 73 (83%) 25 (96%) 40 (80%)
Positive study 46 (52%) 16 (61%) 8 (16%)
CT Thorax 61 (69%) 15 (58%) 13 (26%)
pAVMs present 27 (31%) 5 (19%) 0
Multiple pAVMs 12 (14) 2 (8%) 0
Patients embolised 19 (22%) 0 0
Patients reembolised 9 (10%) 0 0
Embolisation
procedures
28 0 0
MRI Brain 78 (89%) 25 (96%) 38 (76%)
cAVMs present 2 (2.3%) 0 0
White matter
change
9 (10%) 3 (12%) 1 (2%)as epistaxis requiring active management, anaemia from GI
telangiectasia causing blood loss and AVMs in other organs
were infrequent. Among those with possible HHT, 19% had
small pAVMs that require follow up and none had cAVMs.
Symptoms and signs of HHT tend to develop late in
childhood and early adulthood.12 Epistaxis is the most
common symptom,13 as was the case in our population.
pAVMs are prevalent in fifteen to 35% and cAVMs in 10e23%
of patients with HHT.2,5,8,11,14,15 pAVMs are associated with
haemoptysis, haemothorax, migraine, seizure, transient
ischaemic attacks, cerebrovascular accidents and brain
abcesses.2,5,8,9,16 The pathogenesis of pAVM associated
neurological events arises from the loss of the filtering
capacity of the pulmonary circulation with pulmonary right-
to-left shunting resulting in paradoxical emboli passing
directly into the cerebral circulation.2,5 The importance of
detecting AVMs is underscored by a large observational
study carried out by Easey et al. which found that patients
with HHT were twenty-three times more likely to have
a neurological event.17 These neurological complications
occur in up to twenty-seven percent of HHT patients but
are more commonly a result of a pAVM embolic event (61%)
than a direct complication of a cAVM (28%).14
Screening of subjects in our centre detected a pAVM
prevalence of thirty-one percent and a cAVM prevalence of
2.3% in those with definite HHT. Cerebral MRI was performed
in eighty-six percent of our referred population and 89% of
those with definite HHT and was deferred only in those of
young age or with other contraindications to MRI. While the
prevalence of pAVMs in Irish patients is consistent with
international series, the prevalence of cAVMs is considerably
lower. This could relate to the small size of our study pop-
ulation but may also suggest that Irish patients with HHT may
differ genotypically and phenotypically from those in other
countries. Another recent study from Germany has sug-
gested a lower than expected prevalence of cAVMs at 5.3% in
HHT patients.18 Furthermore, there appears to be a much
lower prevalence of both pAVMs and cAVMs in patients with
mutations in the ALK-1 gene (HHT2), compared with those
with mutations in the endoglin gene (HHT1).19 While genetic
screening for known HHT mutations has only been performed
in our centre in 2 families to date (both of whom were
positive for endoglin/HHT type 1 mutations), this study
highlights the importance of prospective genetic screening
combined with continued audit to determine if the apparent
low prevalence of cAVMs is sporadic or real.
In our centre, patients with negative contrast echocardi-
ography do not have further screening for pAVMs, with the
exception of children in whom echocardiography is repeated
in the late teenage years. Patients with positive contrast
echocardiography proceed to unenhanced CT thorax. Where
no pAVM is detected, a repeat CT thorax is scheduled three to
5 years later, on the assumption that small pAVMs may exist
that are not yet detectable on CT thorax. Where a pAVM is
detected, the size of the AVM and in particular the size of the
feeding artery will determine management. Where a pAVM
has a feeding artery greater than 3 mm in diameter, emboli-
sation is performed and a follow up CT Thorax is scheduled
after 6 months to assess involution of the pAVM sac or
replacement with a linear scar.2,9,10 Subsequent CT thorax
follow up can then occur at three to 5 year intervals. Rapid
pAVM enlargement can occur during puberty or pregnancy20
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these periods.10 Prophylactic antibiotic therapy is recom-
mended prior to any dental or surgical procedure in patients
with positive contrast echocardiography or in whom pAVMs
cannot be definitely excluded. Such antibiotic therapy is used
to reduce risk of bacterial embolisation leading to cerebral
abscess.5,11
Thoracic CT detected thirty-two patients with single or
multiple pAVMs, all of whom had definite or possible HHT.
Nineteen patients with single or multiple pAVMs had 28
embolisation procedures performed, with 1e6 pAVMs
embolised per procedure. All patients who required emboli-
sation had definite HHT (three ormore Curac¸ao criteria). Nine
patients required repeat embolisation due to persistence of
a pAVM on CT thorax after initial embolisation. Persistent
pAVMs can result from recanalization of a previously embol-
ised vessel, growth of a missed or previously small accessory
artery, or development of a collateral flow around the
occlusion. This collateral supply may be derived from
a pulmonary artery or from systemic arterial collateral flow
beyond the embolisation (for example, from a bronchial
artery).2 Complications associated with pAVM embolisation
include pleuritic-type chest pain, pulmonary infarction, air
embolism, device migration and deep vein thrombosis.9,21
This study had several limitations. Firstly, the numbers of
patients screened thus far are relatively small. Assuming
a HHT prevalence of 1 in 2500e8000 in an Irish population,
there are 500e1600 prevalent cases in Ireland, indicating
that only a small number of cases have been diagnosed and
screened for visceral AVMs in our centre. Of course, other
incident cases will have been diagnosed sporadically in other
centres. However, it is clear that the majority of patients
with HHTremain undiagnosed in Ireland, as is likely to be the
case in other countries, and it may be that a more compre-
hensive dataset for Ireland would indicate a higher preva-
lence of cAVMs. Secondly, in the present study not all
patients underwent screening for cAVMs (cerebral MRI was
deferred in younger patients) and this could cause a bias as
cAVMs can be present in younger patients. Thirdly, while
patients with a family history of HHTand pAVMs, but without
epistaxis and telangiectasia were considered to have sus-
pected HHT (by Curac¸ao criteria), it is almost certain that
such patients have definite HHT,meaning that some patients
may have been misclassified.
Internationally-published data suggest a prevalence of
fifteen to 35% for pAVMs and 10e23% for cAVMs in patients
with HHT. While the prevalence of pAVMs in our group is
consistent with these data, the prevalence of cAVMs is
considerably lower, suggesting that Irish patients with HHT
may differ genotypically and phenotypically from those in
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